Clinical TrialAug 11, 2026, 08:02 AM
SL Science Publishes Framework for Glioblastoma T Cell Therapy
AI Summary
SL Science Holding Limited announced the publication of a peer-reviewed article in Biomedicines, co-authored by its leadership and Taipei Medical University researchers. The article details a rigorous development framework for γδ T cell therapy in glioblastoma, a severe brain cancer. This publication serves as an industry roadmap and validates SL Science's business strategy and research focus on innovative cellular and gene therapies.
Key Highlights
- SL Science published a peer-reviewed article in Biomedicines.
- Article outlines a rigorous development framework for γδ T cell therapy in glioblastoma.
- Co-authored by SL Science leadership and clinical researchers from Taipei Medical University.
- Publication validates SL Science's overarching business strategy and research direction.
- Framework emphasizes quantitative cell-tracking and serial pharmacodynamic sampling in trials.
- Supports direct, repeated delivery to the tumor cavity to overcome the blood-brain barrier.
- Suggests early trial endpoints focus on verifiable biological activity, not overall survival.
Price Impact
More from SLBT